Verona Pharma's Ohtuvayre launch drives rapid growth and global expansion. Read about the VRNA stock's Q1 results, analyst ...

Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110, up from $95, ...

In our analysis, we have incorporated stocks under $100 that have high growth potential. Using the Finviz screener, the ...

Detailed price information for Verona Pharma Plc ADR (VRNA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Verona Pharma Plc ADR (VRNA-Q) from The Globe and Mail including charting and trades.

Verona Pharma reports $76.3 million Q1 2025 revenue, primarily from Ohtuvayre sales, with significant prescription growth. Quiver AI Summary. Verona Pharma plc reported total net revenue of $76.3 ...

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 ... Verona continues to enroll subjects in a Phase 2 trial to assess the efficacy and safety of ...

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025. Q1 2025 revenue exceeds operating ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the ...

Summary. Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies.

LONDON and RALEIGH, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces ...